Clinical Trials Sponsored by Janssen Pharmaceutica

Total 22196 results

Janssen Pharmaceutical K.K.

Completed

A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection

Mycoses | Candidiasis | Neutropenia | Aspergillosis | Cryptococcosis | Histoplasmosis | Blastomycosis

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain

Pain | Cancer

Japan
Janssen Pharmaceutical K.K.

Completed

A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia

Schizophrenia

Japan
Janssen Pharmaceutical K.K.

Completed

Continuous Treatment Study of Topiramate in Migraine Participants

Migraine

Japan
Janssen Pharmaceutical K.K.

Completed

A Phase 4 Study to Evaluate Pharmacokinetics and Safety of Darunavir Along With Ritonavir in Healthy Male Japanese Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ 10229570-AAA to Evaluate Safety and Tolerability in Japanese Participants With Acne Vulgaris

Acne Vulgaris

Japan
Janssen Pharmaceutical K.K.

Completed

A Long-Term Study of JNS007ER in Patients With Schizophrenia

Schizophrenia
Janssen Pharmaceutical K.K.

Completed

An Exploratory Study of Tramadol Hydrochloride in Patients With Osteoarthritis of the Knee or Low Back Pain

Osteoarthritis | Low Back Pain
Janssen Pharmaceutical K.K.

Completed

A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia

Schizophrenia
Janssen Pharmaceutical K.K.

Completed

A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients

Schizophrenia
Janssen Pharmaceutical K.K.

Recruiting

A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)

Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)

Taiwan, Korea, Republic of, Japan
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (YATAGARASU)

Salivary Gland Neoplasms

Japan
Janssen Pharmaceutical K.K.

Terminated

A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments

Dermatomyositis | Polymyositis

Japan
Janssen Pharmaceutical K.K.

Terminated

A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)

Takayasu Arteritis

Japan
Janssen Pharmaceutical K.K.

Terminated

A Study of JNJ-75220795 in Japanese Participants

Fatty Liver

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-77242113 in Healthy Japanese and Chinese Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of Ad26.COV2.S in Adults (COVID-19)

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-61393215 in Healthy Japanese Male Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV) Vaccine in Japanese Adults Aged 60 Years and Older

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Pustular Psoriasis

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-63733657 in Healthy Japanese Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis

Palmoplantar Pustulosis

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Guselkumab Following a Single Intravenous Administration in Healthy Japanese Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy

Metastatic Castration-Resistant Prostate Cancer

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single Oral Administration of Darunavir/Cobicistat Fixed-Dose Combination in Healthy Japanese Adult Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer

Prostatic Neoplasms

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Withdrawn

A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR6261 in Japanese Healthy Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Janssen Pharmaceutical K.K.

Terminated

A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis

Dermatitis, Atopic

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis

Palmoplantaris Pustulosis

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate the Safety and Efficacy of Ultiva (Remifentanil Hydrochloride) in Pediatric Participants General Anesthetised

Anesthesia

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder

Autistic Disorder in Children and Adolescents

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia

Schizophrenia

Japan
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease

Alzheimer's Disease

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy

Hepatitis C, Chronic

Japan
Janssen Pharmaceutical K.K.

Completed

An Exploratory Study of Nesiritide in Participants With Acute Heart Failure

Heart Failure, Congestive

Japan
Janssen Pharmaceutical K.K.

Completed

A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy

Hepatitis C, Chronic

Japan
Janssen Pharmaceutical K.K.

Completed

A Confirmatory Study of Fentanyl in Participants With Osteoarthritis or Low Back Pain

Osteoarthritis | Low Back Pain | Chronic Pain

Japan
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of Fentanyl in Participants With Chronic Pain

Chronic Pain

Japan
Janssen Pharmaceutical K.K.

Completed

A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer Pain

Pain | Cancer

Japan
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study for Tapentadol Extended Release (JNS024ER) in Chronic Pain Participants

Pain | Back Pain | Low Back Pain | Osteoarthritis, Knee

Japan
Janssen Pharmaceutical K.K.

Completed

A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants

Neoplasms

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate Skin Irritation and Photo Irritation of JNJ 10229570-AAA on Intact Skin of Japanese Healthy Male Participants

Healthy Volunteers

Japan
Janssen Pharmaceutical K.K.

Terminated

A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease

Dementia | Alzheimer's Disease
Janssen Pharmaceutical K.K.

Completed

An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy

Multiple Myeloma
Janssen Pharmaceutical K.K.

Completed

A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients

Multiple Myeloma | Relapse | Refractory
Janssen Pharmaceutical K.K.

Completed

Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based Chemotherapy

Ovarian Neoplasms
Janssen Pharmaceutical K.K.

Completed

Phase III Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Chronic Intractable Pain- Assessment of Effectiveness, Safety and Pharmacokinetics

Pain, Intractable

3

Subscribe